138 related articles for article (PubMed ID: 36438853)
1. Structural insight and analysis of TLR4 interactions with IAXO-102, TAK-242 and SN-38: an in silico approach.
Tam JSY; Pei JV; Coller JK; Prestidge CA; Bowen JM
In Silico Pharmacol; 2023; 11(1):1. PubMed ID: 36438853
[TBL] [Abstract][Full Text] [Related]
2. Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity.
Tam JSY; Crame EE; Elz AS; Coller JK; Wignall A; Prestidge CA; Bowen JM
Cancer Chemother Pharmacol; 2022 Sep; 90(3):267-278. PubMed ID: 35962138
[TBL] [Abstract][Full Text] [Related]
3. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4.
Wong DVT; Ribeiro-Filho HV; Wanderley CWS; Leite CAVG; Lima JB; Assef ANB; Cajado AG; Batista GLP; González RH; Silva KO; Borges LPC; Alencar NMN; Wilke DV; Cunha TM; Figueira ACM; Cunha FQ; Lima-Júnior RCP
Cancer Chemother Pharmacol; 2019 Aug; 84(2):287-298. PubMed ID: 31011814
[TBL] [Abstract][Full Text] [Related]
4. Investigation of TLR4 Antagonists for Prevention of Intestinal Inflammation.
Tam JSY; Coller JK; Prestidge CA; Bowen JM
Inflammation; 2023 Feb; 46(1):103-114. PubMed ID: 35867263
[TBL] [Abstract][Full Text] [Related]
5. A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms development.
Huggins C; Pearce S; Peri F; Neumann F; Cockerill G; Pirianov G
Atherosclerosis; 2015 Oct; 242(2):563-70. PubMed ID: 26318106
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
Mishra V; Pathak C
J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
[TBL] [Abstract][Full Text] [Related]
7. Selective Toll-Like Receptor 4 Antagonists Prevent Acute Blood-Brain Barrier Disruption After Subarachnoid Hemorrhage in Mice.
Okada T; Kawakita F; Nishikawa H; Nakano F; Liu L; Suzuki H
Mol Neurobiol; 2019 Feb; 56(2):976-985. PubMed ID: 29855971
[TBL] [Abstract][Full Text] [Related]
8. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model.
Takashima K; Matsunaga N; Yoshimatsu M; Hazeki K; Kaisho T; Uekata M; Hazeki O; Akira S; Iizawa Y; Ii M
Br J Pharmacol; 2009 Aug; 157(7):1250-62. PubMed ID: 19563534
[TBL] [Abstract][Full Text] [Related]
9. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules.
Matsunaga N; Tsuchimori N; Matsumoto T; Ii M
Mol Pharmacol; 2011 Jan; 79(1):34-41. PubMed ID: 20881006
[TBL] [Abstract][Full Text] [Related]
10. Glycolipid-based TLR4 Modulators and Fluorescent Probes: Rational Design, Synthesis, and Biological Properties.
Ciaramelli C; Calabrese V; Sestito SE; Pérez-Regidor L; Klett J; Oblak A; Jerala R; Piazza M; Martín-Santamaría S; Peri F
Chem Biol Drug Des; 2016 Aug; 88(2):217-29. PubMed ID: 26896420
[TBL] [Abstract][Full Text] [Related]
11. In Silico Insights on the Pro-Inflammatory Potential of Polycyclic Aromatic Hydrocarbons and the Prospective Anti-Inflammatory Capacity of
Julaton T; Taclendo A; Oyong G; Rempillo O; Galvez MC; Vallar E
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886440
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure.
Engelmann C; Sheikh M; Sharma S; Kondo T; Loeffler-Wirth H; Zheng YB; Novelli S; Hall A; Kerbert AJC; Macnaughtan J; Mookerjee R; Habtesion A; Davies N; Ali T; Gupta S; Andreola F; Jalan R
J Hepatol; 2020 Jul; 73(1):102-112. PubMed ID: 31987990
[TBL] [Abstract][Full Text] [Related]
13. Dissecting the Innate Immune Recognition of Opioid Inactive Isomer (+)-Naltrexone Derived Toll-like Receptor 4 (TLR4) Antagonists.
Zhang X; Cui F; Chen H; Zhang T; Yang K; Wang Y; Jiang Z; Rice KC; Watkins LR; Hutchinson MR; Li Y; Peng Y; Wang X
J Chem Inf Model; 2018 Apr; 58(4):816-825. PubMed ID: 29518316
[TBL] [Abstract][Full Text] [Related]
14. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain.
Kawamoto T; Ii M; Kitazaki T; Iizawa Y; Kimura H
Eur J Pharmacol; 2008 Apr; 584(1):40-8. PubMed ID: 18299127
[TBL] [Abstract][Full Text] [Related]
15. TAK-242, a small-molecule inhibitor of Toll-like receptor 4 signalling, unveils similarities and differences in lipopolysaccharide- and lipid-induced inflammation and insulin resistance in muscle cells.
Hussey SE; Liang H; Costford SR; Klip A; DeFronzo RA; Sanchez-Avila A; Ely B; Musi N
Biosci Rep; 2012 Nov; 33(1):37-47. PubMed ID: 23050932
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid).
Kashani B; Zandi Z; Bashash D; Zaghal A; Momeny M; Poursani EM; Pourbagheri-Sigaroodi A; Mousavi SA; Ghaffari SH
Cancer Chemother Pharmacol; 2020 Jan; 85(1):47-59. PubMed ID: 31786654
[TBL] [Abstract][Full Text] [Related]
17. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.
Kashani B; Zandi Z; Karimzadeh MR; Bashash D; Nasrollahzadeh A; Ghaffari SH
Immunol Res; 2019 Dec; 67(6):505-516. PubMed ID: 32026322
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan decreases intestinal UDP-glucuronosyltransferase (UGT) 1A1 via TLR4/MyD88 pathway prior to the onset of diarrhea.
Tao G; Dagher F; Li L; Singh R; Hu M; Ghose R
Food Chem Toxicol; 2022 Aug; 166():113246. PubMed ID: 35728726
[TBL] [Abstract][Full Text] [Related]
19. In Silico Approach in the Evaluation of Pro-Inflammatory Potential of Polycyclic Aromatic Hydrocarbons and Volatile Organic Compounds through Binding Affinity to the Human Toll-Like Receptor 4.
Cabral MB; Dela Cruz CJ; Sato Y; Oyong G; Rempillo O; Galvez MC; Vallar E
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886213
[TBL] [Abstract][Full Text] [Related]
20. A structural insight into the negative effects of opioids in analgesia by modulating the TLR4 signaling: An in silico approach.
Shah M; Anwar MA; Yesudhas D; Krishnan J; Choi S
Sci Rep; 2016 Dec; 6():39271. PubMed ID: 27982096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
